Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7172-7179

  Shrestha, Neha ^a   Shahbazi, Mohammad Ali ^a   Araújo, Francisca ^a,b,c   Zhang, Hongbo ^a   Mäkilä, Ermei M ^a,d   Kauppila, Jussi ^d   Sarmento, Bruno ^b,e   Salonen, Jarno J ^d   Hirvonen, Jouni T ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

Cell monolayers; Chitosan; Diabetes; Insulin; Microparticles; Porous silicon

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADATION; BODY FLUIDS; CELL MEMBRANES; CHITOSAN; CYTOLOGY; DRUG DELIVERY; MEDICAL PROBLEMS; MONOLAYERS; MULTILAYERS; POROUS SILICON; PROTEINS;

APPARENT PERMEABILITIES; CELL MONOLAYERS; DRUG DELIVERY SYSTEM; ENHANCED PERMEABILITY; INTESTINAL PERMEATIONS; MICRO-PARTICLES; PARTICULATE SYSTEMS; PHYSICOCHEMICAL PROPERTY;

INSULIN;

10 UNDECENOIC ACID; CHITOSAN; INSULIN; POROUS SILICON; SILICON; UNCLASSIFIED DRUG; NANOPARTICLE;

ARTICLE; CACO 2 CELL LINE; CELL INTERACTION; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HT 29 CELL LINE; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE CELL; MEMBRANE PERMEABILITY; MUCUS; PRIORITY JOURNAL; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; INTESTINE; METABOLISM; PARTICLE SIZE; PERMEABILITY; POROSITY; PROCEDURES; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY;

CACO-2 CELLS; CELL SURVIVAL; CHITOSAN; DRUG DELIVERY SYSTEMS; HT29 CELLS; HUMANS; INSULIN; INTESTINAL ABSORPTION; INTESTINES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; POROSITY; SILICON; SURFACE PROPERTIES;

EID: 84902079022     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.104     Document Type: Article

References (51)

1. Chen M.C., Sonaje K., Chen K.J., Sung H.W. Areview of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32:9826-9838.
2. Junginger H.E., Verhoef J.C. Macromolecules as safe penetration enhancers for hydrophilic drugs - a fiction?. Pharm Sci Technol Today 1998, 1:370-376.
3. Hoffman A., Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet 1997, 33:285-301.
4. Fonte P., Araújo F., Reis S., Sarmento B. Oral insulin delivery: how far are we?. JDiabetes Sci Technol 2013, 7:520-531.
5. Carino G.P., Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999, 35:249-257.
6. Foraker A.B., Walczak R.J., Cohen M.H., Boiarski T.A., Grove C.F., Swaan P.W. Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res 2003, 20:110-116.
7. Sarmento B., Martins S., Ferreira D., Souto E.B. Oral insulin delivery by means of solid lipid nanoparticles. Int J Nanomed 2007, 2:743-749.
8. Sarmento B., Ribeiro A., Veiga F., Sampaio P., Neufeld R., Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007, 24:2198-2206.
9. Diabetology Axess™ oral delivery system 2014, [cited 2014 22 January]. Available from:. http://www.diabetology.co.uk.
10. Li X., Guo S., Zhu C., Zhu Q., Gan Y., Rantanen J., et al. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 2013, 34:9678-9687.
11. Lee H., Jeong C., Ghafoor K., Cho S., Park J. Oral delivery of insulin using chitosan capsules cross-linked with phytic acid. Biomed Mater Eng 2011, 21:25-36.
12. Cui F., Qian F., Zhao Z., Yin L., Tang C., Yin C. Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles. Biomacromolecules 2009, 10:1253-1258.
13. Wang S.B. Ordered mesoporous materials for drug delivery. Microporous Mesoporous Mater 2009, 117:1-9.
14. Santos H.A., Bimbo L.M., Lehto V.P., Airaksinen A.J., Salonen J., Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol 2011, 8:228-249.
15. Salonen J., Kaukonen A.M., Hirvonen J., Lehto V.P. Mesoporous silicon in drug delivery applications. JPharm Sci 2008, 97:632-653.
16. Canham L.T. Bioactive silicon structure fabrication through nanoetching techniques. Adv Mater 1995, 7:1033.
17. Bimbo L.M., Denisova O.V., Mäkilä E., Kaasalainen M., De Brabander J.K., Hirvonen J., et al. Inhibition of influenza a virus infection invitro by saliphenylhalamide-loaded porous silicon nanoparticles. ACS Nano 2013, 7:6884-6893.
18. Kilpeläinen M., Mönkäre J., Vlasova M.A., Riikonen J., Lehto V.P., Salonen J., et al. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. Eur J Pharm Biopharm 2011, 77:20-25.
19. Kinnari P., Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm 2011, 414:148-156.
20. Kovalainen M., Mönkäre J., Mäkilä E., Salonen J., Lehto V.P., Herzig K.H., et al. Mesoporous silicon (PSi) for sustained peptide delivery: effect of PSi microparticle surface chemistry on peptide YY3-36 release. Pharm Res 2012, 29:837-846.
21. Liu D., Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz-Blanco B., et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. JControl Release 2013, 170:268-278.
22. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Bjorkqvist M., Heikkilä T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. JControl Release 2005, 108:362-374.
23. Santos H.A., Riikonen J., Salonen J., Mäkilä E., Heikkilä T., Laaksonen T., et al. Invitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 2010, 6:2721-2731.
24. Kovalainen M., Mönkäre J., Kaasalainen M., Riikonen J., Lehto V.P., Salonen J., et al. Development of porous silicon nanocarriers for parenteral peptide delivery. Mol Pharm 2013, 10:353-359.
25. Kilpeläinen M., Riikonen J., Vlasova M.A., Huotari A., Lehto V.P., Salonen J., et al. Invivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. JControl Release 2009, 137:166-170.
26. Huotari A., Xu W.J., Mönkäre J., Kovalainen M., Herzig K.H., Lehto V.P., et al. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity. Int J Pharm 2013, 454:67-73.
27. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Mäkilä E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
28. Salonen J., Mäkilä E., Riikonen J., Heikkilä T., Lehto V.P. Controlled enlargement of pores by annealing of porous silicon. Phys Status Solidi A 2009, 206:1313-1317.
29. Sonaje K., Lin K.J., Tseng M.T., Wey S.P., Su F.Y., Chuang E.Y., et al. Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011, 32:8712-8721.
30. Fonte P., Andrade F., Araújo F., Andrade C., das Neves J., Sarmento B. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol 2012, 508:295-314.
31. Sarmento B., Andrade F., da Silva S.B., Rodrigues F., das Neves J., Ferreira D. Cell-based invitro models for predicting drug permeability. Expert Opin Drug Metab 2012, 8:607-621.
32. Bimbo L.M., Makila E., Raula J., Laaksonen T., Laaksonen P., Strommer K., et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011, 32:9089-9099.
33. Brunauer S., Emmett P.H., Teller E. Adsorption of gases in multimolecular layers. JAm Chem Soc 1938, 60:309-319.
34. Sarmento B., Ribeiro A., Veiga F., Ferreira D. Development and validation of a rapid reversed-phase HPLC method for the determination of insulin from nanoparticulate systems. Biomed Chromatogr 2006, 20:898-903.
35. Shahbazi M.A., Hamidi M., Mäkilä E.M., Zhang H., Almeida P.V., Kaasalainen M., et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013, 34:7776-7789.
36. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
37. Kumari A., Yadav S.K. Cellular interactions of therapeutically delivered nanoparticles. Expert Opin Drug Deliv 2011, 8:141-151.
38. Nel A.E., Madler L., Velegol D., Xia T., Hoek E.M., Somasundaran P., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009, 8:543-557.
39. Antunes F., Andrade F., Araújo F., Ferreira D., Sarmento B. Establishment of a triple co-culture invitro cell models to study intestinal absorption of peptide drugs. Eur J Pharm Biopharm 2013, 83:427-435.
40. Fernandes M., Gonçalves I.C., Nardecchia S., Amaral I.F., Barbosa M.A., Martins M.C.L. Modulation of stability and mucoadhesive properties of chitosan microspheres for therapeutic gastric application. Int J Pharm 2013, 454:116-124.
41. Sigurdsson H.H., Loftsson T., Lehr C.M. Assessment of mucoadhesion by a resonant mirror biosensor. Int J Pharm 2006, 325:75-81.
42. Hagesaether E., Hiorth M., Sande S.A. Mucoadhesion and drug permeability of free mixed films of pectin and chitosan: an invitro and exvivo study. Eur J Pharm Biopharm 2009, 71:325-331.
43. Hilgendorf C., Spahn-Langguth H., Regardh C.G., Lipka E., Amidon G.L., Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. JPharm Sci 2000, 89:63-75.
44. Shahbazi M.A., Santos H.A. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 2013, 14:28-56.
45. Zhang H., Shahbazi M.-A., Mäkilä E.M., da Silva T.H., Reis R.L., Salonen J.J., et al. Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine. Biomaterials 2013, 34:9210-9219.
46. Pillai O., Panchagnula R. Insulin therapies - past, present and future. Drug Discov Today 2001, 6:1056-1061.
47. Chen M.C., Mi F.L., Liao Z.X., Hsiao C.W., Sonaje K., Chung M.F., et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliv Rev 2013, 65:865-879.
48. Sonaje K., Chuang E.Y., Lin K.J., Yen T.C., Su F.Y., Tseng M.T., et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm 2012, 9:1271-1279.
49. Hsu L.W., Lee P.L., Chen C.T., Mi F.L., Juang J.H., Hwang S.M., et al. Elucidating the signaling mechanism of an epithelial tight-junction opening induced by chitosan. Biomaterials 2012, 33:6254-6263.
50. Pillai C.K.S., Paul W., Sharma C.P. Chitin and chitosan polymers: chemistry, solubility and fiber formation. Prog Polym Sci 2009, 34:641-678.
51. Sakloetsakun D., Perera G., Hombach J., Millotti G., Bernkop-Schnurch A. The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with chitosan-4-thiobutylamidine conjugate. AAPS PharmSciTech 2010, 11:1185-1192.